A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity

Chimeric antigen receptor T cells represent a breakthrough treatment in hematologic malignancies, but insufficient level of cytotoxicity and persistence of T cells might compromise success. Authors show here that a recombinant long acting form of interleukin-7 enhances proliferation, persistence and...

Full description

Bibliographic Details
Main Authors: Miriam Y. Kim, Reyka Jayasinghe, Jessica M. Devenport, Julie K. Ritchey, Michael P. Rettig, Julie O’Neal, Karl W. Staser, Krista M. Kennerly, Alun J. Carter, Feng Gao, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio
Format: Article
Language:English
Published: Nature Portfolio 2022-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-30860-0

Internet

https://doi.org/10.1038/s41467-022-30860-0

Similar Items